(Information sent by the signatory company)
CHENGDU, China, Jan. 24, 2024/PRNewswire/ — Kicking off the New Year with notable achievements, Chengdu-based WestGene made a significant impact at the third mRNA-based Therapeutics Summit in Berlin, Germany. Recognized for her pivotal role in mRNA research, Dr. Xiangrong Song, co-founder and CEO of WestGene, presented the latest developments in the company’s oncology sector, with a focus on cancer vaccines based on mRNA.
The Summit, which will be held from January 23 to 25, is a key event in the field of mRNA drug development and attracts more than 200 specialists from various parts of the world. This year’s discussions highlighted the versatility of mRNA technology in addressing novel diseases and emphasized the importance of global collaboration in drug development and access. Insights from influential bodies such as the WHO, CEPI and EMA, as well as industry giants such as Pfizer, Sanofi, Moderna, Merck, BioNTech and CureVac, focused on the application of AI and machine learning in mRNA research , overcoming regulatory complexities and progress. in therapeutic development and manufacturing.
In her keynote address, Dr. Song discussed updates and interim data on mRNA-based cancer vaccines targeting EBV-associated cancers and HBV-positive liver cancer. She discussed WestGene’s advances in treating specific cancers such as nasopharyngeal carcinoma, NKT lymphoma, HBV-related hepatocellular carcinoma, and colorectal cancer, highlighting the safety and efficacy established by IIT clinical trial data. This speech underscored the transformative impact of WestGene’s mRNA therapy in the field of oncology.
The EBV-associated cancer vaccine, a prominent project in WestGene’s portfolio of more than 20 mRNA initiatives, has overcome significant hurdles, including tumor vaccine efficacy and immunogenicity. Its rapid production and cost-effectiveness, along with its high efficacy and low toxicity, significantly improve patient accessibility and provide a more viable treatment option for a broader patient base. This innovation was especially recognized at the 2022 National Disruptive Technology Innovation Competition, where WestGene triumphed as the sole winner in the mRNA category among 2,800 entrants, cementing its status as a pioneer in the biotech industry in China.
Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapy. Focusing on the development of cutting-edge mRNA therapies, the company aims to consolidate its position in the global biopharmaceutical market, supported by its strong technological infrastructure and exclusive intellectual property rights.
2023 marked a year of monumental progress for WestGene, with the acquisition of a US patent for its innovative LNP delivery technology and government approval for a key project in AI-driven mRNA drug design for the development of vaccines against cancer and protein replacement. This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical research and innovation.
Photo – https://mma.prnewswire.com/media/2325862/WestGene.jpg
View original content: https://www.prnewswire.com/news-releases/westgene-encabeza-los-avances-en-oncologia-en-la-3-cumbre-de-terapeutica-basada-en-arnm-302043499.html
